RNS Announcements

2023

ProBiotix Health plc (AQSE: PBX), a life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions, announces its unaudited results for the six months to 30 June 2023.

Highlights (including post period end)

• Industry leader Steen Andersen appointed as CEO, effective as of 2 January 2023
• Financially robust with no debt and a strong balance sheet
• Expansion of leadership team with the appointment of Niels Peter Bak as Head of Product Management
• Closing of long-term commercial agreement with third largest supplement brand in Germany for CholBiome® CH launch
• Successful completion and publication of the second clinical study on the benefits of LP_LDL® intake on cardiovascular disease biomarkers
• Exclusive distribution agreement with Trans Chem to cover the Australian and New Zealand probiotics market

Steen Andersen,  CEO of ProBiotix, commented: “Since I took over as CEO in January 2023, my focus has been on building and developing a defined strategy whereby we are looking to become a solutions provider of finished probiotic products in consumer formats. My objective is to build ProBiotix into a £10m plus turnover company, marketing our products both under our own brands and partner private labels. We are excited about the future of the Company and remain committed to providing long term value to our shareholders.”

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

2022

ProBiotix Health plc (AQSE: PBX), a life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions, announces its unaudited results for the six months to 30 June 2023.

Highlights (including post period end)

• Industry leader Steen Andersen appointed as CEO, effective as of 2 January 2023
• Financially robust with no debt and a strong balance sheet
• Expansion of leadership team with the appointment of Niels Peter Bak as Head of Product Management
• Closing of long-term commercial agreement with third largest supplement brand in Germany for CholBiome® CH launch
• Successful completion and publication of the second clinical study on the benefits of LP_LDL® intake on cardiovascular disease biomarkers
• Exclusive distribution agreement with Trans Chem to cover the Australian and New Zealand probiotics market

Steen Andersen,  CEO of ProBiotix, commented: “Since I took over as CEO in January 2023, my focus has been on building and developing a defined strategy whereby we are looking to become a solutions provider of finished probiotic products in consumer formats. My objective is to build ProBiotix into a £10m plus turnover company, marketing our products both under our own brands and partner private labels. We are excited about the future of the Company and remain committed to providing long term value to our shareholders.”

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact: